Publication: Effective Pseudomonas aeruginosa eradication in cystic fibrosis: multicenter study
| dc.contributor.coauthor | Guliyeva, Aynur | |
| dc.contributor.coauthor | Yegit, Cansu Yilmaz | |
| dc.contributor.coauthor | Yanaz, Muruvvet | |
| dc.contributor.coauthor | Kalyoncu, Mine | |
| dc.contributor.coauthor | Balci, Merve Selcuk | |
| dc.contributor.coauthor | Karabulut, Seyda | |
| dc.contributor.coauthor | Ergenekon, Almala Pinar | |
| dc.contributor.coauthor | Tastan, Gamze | |
| dc.contributor.coauthor | Uzunoglu, Burcu | |
| dc.contributor.coauthor | Arslan, Huseyin | |
| dc.contributor.coauthor | Yazan, Hakan | |
| dc.contributor.coauthor | Bilgin, Gulay Bas | |
| dc.contributor.coauthor | Sakalli, Ayse Ayzit Kilinc | |
| dc.contributor.coauthor | Cakir, Erkan | |
| dc.contributor.coauthor | Girit, Saniye | |
| dc.contributor.coauthor | Uyan, Zeynep Seda | |
| dc.contributor.coauthor | Gokdemir, Yasemin | |
| dc.contributor.coauthor | Eralp, Ela Erdem | |
| dc.contributor.coauthor | Karakoc, Fazilet | |
| dc.contributor.coauthor | Karadag, Bulent | |
| dc.contributor.department | School of Medicine | |
| dc.contributor.kuauthor | Köstereli, Ebru | |
| dc.contributor.schoolcollegeinstitute | SCHOOL OF MEDICINE | |
| dc.date.accessioned | 2025-09-10T04:58:37Z | |
| dc.date.available | 2025-09-09 | |
| dc.date.issued | 2025 | |
| dc.description.abstract | Background: Pseudomonas aeruginosa (PA) eradication is crucial in cystic fibrosis (CF) management. At our center, the success rate was 21.6%, prompting a revised eradication protocol to evaluate a new regimen.Methods: Cystic fibrosis patients with first-time PA detection were included. Nonmucoid PA cases received oral ciprofloxacin (3 weeks) and inhaled tobramycin (1 month). For mucoid PA or failed eradication, ciprofloxacin (3 weeks) and extended nebulized therapy (3 months, alternating tobramycin/colistin) were used. Intravenous antibiotics were given to unwell patients.Results: Among 109 CF patients (median age: 6 years), 79 (72.5%) achieved successful eradication. Oral ciprofloxacin and tobramycin inhalation were used in 66 patients (60.6%), extended nebulized therapy in 26 (23.8%), and intravenous antibiotics in 17(15.6%).Conclusion: The revised protocol achieved a high PA eradication rate in CF patients. Adapting treatment regimens based on PA characteristics and patient condition can optimize outcomes and improve CF management. | |
| dc.description.fulltext | No | |
| dc.description.harvestedfrom | Manual | |
| dc.description.indexedby | WOS | |
| dc.description.indexedby | PubMed | |
| dc.description.indexedby | Scopus | |
| dc.description.publisherscope | International | |
| dc.description.readpublish | N/A | |
| dc.description.sponsoredbyTubitakEu | N/A | |
| dc.identifier.doi | 10.1177/00099228251351699 | |
| dc.identifier.eissn | 1938-2707 | |
| dc.identifier.embargo | No | |
| dc.identifier.endpage | 1588 | |
| dc.identifier.issn | 0009-9228 | |
| dc.identifier.issue | 11 | |
| dc.identifier.pubmed | 4057604 | |
| dc.identifier.quartile | Q4 | |
| dc.identifier.scopus | 2-s2.0-105012547978 | |
| dc.identifier.startpage | 1581 | |
| dc.identifier.uri | https://doi.org/10.1177/00099228251351699 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.14288/30337 | |
| dc.identifier.volume | 64 | |
| dc.identifier.wos | 001517976000001 | |
| dc.keywords | Cystic fibrosis | |
| dc.keywords | Eradication | |
| dc.keywords | Pseudomonas aeruginosa | |
| dc.language.iso | eng | |
| dc.publisher | Sage Publications Inc | |
| dc.relation.affiliation | Koç University | |
| dc.relation.collection | Koç University Institutional Repository | |
| dc.relation.ispartof | Clinical Pediatrics | |
| dc.subject | Pediatrics | |
| dc.title | Effective Pseudomonas aeruginosa eradication in cystic fibrosis: multicenter study | |
| dc.type | Journal Article | |
| dspace.entity.type | Publication | |
| person.familyName | Köstereli | |
| person.givenName | Ebru | |
| relation.isOrgUnitOfPublication | d02929e1-2a70-44f0-ae17-7819f587bedd | |
| relation.isOrgUnitOfPublication.latestForDiscovery | d02929e1-2a70-44f0-ae17-7819f587bedd | |
| relation.isParentOrgUnitOfPublication | 17f2dc8e-6e54-4fa8-b5e0-d6415123a93e | |
| relation.isParentOrgUnitOfPublication.latestForDiscovery | 17f2dc8e-6e54-4fa8-b5e0-d6415123a93e |
